141 related articles for article (PubMed ID: 20680678)
41. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer.
Huang KT; Takano EA; Mikeska T; Byrne DJ; Dobrovic A; Fox SB
Breast Cancer Res Treat; 2011 Nov; 130(1):319-29. PubMed ID: 21755341
[TBL] [Abstract][Full Text] [Related]
42. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
43. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
Banks RE; Tirukonda P; Taylor C; Hornigold N; Astuti D; Cohen D; Maher ER; Stanley AJ; Harnden P; Joyce A; Knowles M; Selby PJ
Cancer Res; 2006 Feb; 66(4):2000-11. PubMed ID: 16488999
[TBL] [Abstract][Full Text] [Related]
44. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
45. Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma.
Łuczak MW; Roszak A; Pawlik P; Kędzia H; Lianeri M; Jagodziński PP
Oncol Rep; 2011 Nov; 26(5):1259-64. PubMed ID: 21887475
[TBL] [Abstract][Full Text] [Related]
46. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
47. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity.
Blankenship C; Naglich JG; Whaley JM; Seizinger B; Kley N
Oncogene; 1999 Feb; 18(8):1529-35. PubMed ID: 10102622
[TBL] [Abstract][Full Text] [Related]
48. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor.
Zagzag D; Krishnamachary B; Yee H; Okuyama H; Chiriboga L; Ali MA; Melamed J; Semenza GL
Cancer Res; 2005 Jul; 65(14):6178-88. PubMed ID: 16024619
[TBL] [Abstract][Full Text] [Related]
49. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
50. The von Hippel-Lindau tumour-suppressor protein interaction with protein kinase Cdelta.
Iturrioz X; Durgan J; Calleja V; Larijani B; Okuda H; Whelan R; Parker PJ
Biochem J; 2006 Jul; 397(1):109-20. PubMed ID: 16669786
[TBL] [Abstract][Full Text] [Related]
51. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
52. Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.
Nguyen HC; Yang H; Fribourgh JL; Wolfe LS; Xiong Y
Structure; 2015 Mar; 23(3):441-449. PubMed ID: 25661653
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
[TBL] [Abstract][Full Text] [Related]
54. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
55. Proteomic dissection of the von Hippel-Lindau (VHL) interactome.
Lai Y; Song M; Hakala K; Weintraub ST; Shiio Y
J Proteome Res; 2011 Nov; 10(11):5175-82. PubMed ID: 21942715
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
57. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
Aso T; Yamazaki K; Aigaki T; Kitajima S
Biochem Biophys Res Commun; 2000 Sep; 276(1):355-61. PubMed ID: 11006129
[TBL] [Abstract][Full Text] [Related]
58. VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma.
Linehan WM; Rubin JS; Bottaro DP
Int J Biochem Cell Biol; 2009 Apr; 41(4):753-6. PubMed ID: 18950731
[TBL] [Abstract][Full Text] [Related]
59. Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex.
Cardote TAF; Gadd MS; Ciulli A
Structure; 2017 Jun; 25(6):901-911.e3. PubMed ID: 28591624
[TBL] [Abstract][Full Text] [Related]
60. VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation.
Artemov AV; Zhigalova N; Zhenilo S; Mazur AM; Prokhortchouk EB
Sci Rep; 2018 Jul; 8(1):10667. PubMed ID: 30006568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
